公开(公告)号：US20240308960A1

公开(公告)日：2024-09-19

申请号：US18563776

申请日：2022-05-26

申请人： Sumitomo Pharma Co., Ltd.

发明人： Masafumi KOMIYA ,  Shunichiro UESUGI ,  Eiji IDEUE ,  Shoukou LEE ,  Daisuke TANAKA ,  Yuta FUNAKOSHI

IPC分类号： C07D211/22 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/55 ,  A61K31/551 ,  C07D211/16 ,  C07D211/26 ,  C07D211/46 ,  C07D221/04 ,  C07D223/16 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

CPC分类号： C07D211/22 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/55 ,  A61K31/551 ,  C07D211/16 ,  C07D211/26 ,  C07D211/46 ,  C07D221/04 ,  C07D223/16 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

摘要： The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin receptor type 2, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing a disease such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome.